Medtronic takes Valiant thoracic graft to EU:
This article was originally published in Clinica
Medtronic has launched for sale in Europe its Valiant thoracic stent graft and accompanying Xcelerant delivery system for the minimally invasive treatment of diseases of the thoracic aorta. The graft is more conformable than earlier generation devices, and the new delivery system enables precise transluminal deployment of the implant, said the firm. It also offers more size and end configuration options, giving physicians a greater opportunity of matching the graft to the patient's anatomy. The device is available in covered graft lengths of up to 20cm "for maximum lesion coverage and the use of fewer graft segments to complete procedures", said the firm. Every year in Europe, descending thoracic aortic lesions are diagnosed in around 16,000 patients, many of whom are at risk if they undergo traditional open surgery, Medtronic added.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.